Oxidants and antioxidants as therapeutic targets in chronic obstructive pulmonary disease
- PMID: 10556172
- DOI: 10.1164/ajrccm.160.supplement_1.15
Oxidants and antioxidants as therapeutic targets in chronic obstructive pulmonary disease
Abstract
There is now increasing evidence that an oxidant/antioxidant imbalance, in favor of oxidants, occurs in chronic obstructive pulmonary disease (COPD). Evidence is also accumulating that oxidative stress is a critical event in the pathogenesis of this condition. A large number of studies have demonstrated an increased oxidant burden and consequently increased markers of oxidative stress in the airspaces, breath, blood, and urine of smokers and of patients with COPD. There are several events related to oxidative stress, which are important in the pathogenesis of COPD. These include oxidative inactivation of antiproteinases, airspace epithelial injury, increased sequestration of neutrophils in the pulmonary microvasculature, and gene expression of proinflammatory mediators. Oxidative processes have a fundamental role in the inflammation of smokers and patients with COPD, through redox-sensitive transcription factors such as NF-kappaB and AP-1, which regulate the genes for proinflammatory mediators and protective mechanisms, such as antioxidant gene expression. In addition to the oxidative stress produced by cigarette smoking, dietary deficiency in antioxidants is related to the development of airflow limitation, and hence dietary supplementation may be a beneficial therapeutic intervention in this condition. The use of antioxidants with good bioavailability or molecules that have antioxidant enzyme activity may be treatments that not only protect against the direct injurious effects of oxidants, but may fundamentally alter the inflammatory events that are thought to play an important part in the pathogenesis of COPD. MacNee W, Rahman I. Oxidants and antioxidants as therapeutic targets in chronic obstructive pulmonary disease.
Similar articles
-
Oxidants/antioxidants and chronic obstructive pulmonary disease: pathogenesis to therapy.Novartis Found Symp. 2001;234:169-85; discussion 185-8. Novartis Found Symp. 2001. PMID: 11199095 Review.
-
Oxidants/antioxidants and COPD.Chest. 2000 May;117(5 Suppl 1):303S-17S. doi: 10.1378/chest.117.5_suppl_1.303s-a. Chest. 2000. PMID: 10843965 Review.
-
Is oxidative stress central to the pathogenesis of chronic obstructive pulmonary disease?Trends Mol Med. 2001 Feb;7(2):55-62. doi: 10.1016/s1471-4914(01)01912-8. Trends Mol Med. 2001. PMID: 11286755
-
Pulmonary and systemic oxidant/antioxidant imbalance in chronic obstructive pulmonary disease.Proc Am Thorac Soc. 2005;2(1):50-60. doi: 10.1513/pats.200411-056SF. Proc Am Thorac Soc. 2005. PMID: 16113469 Review.
-
Oxidative stress and gene transcription in asthma and chronic obstructive pulmonary disease: antioxidant therapeutic targets.Curr Drug Targets Inflamm Allergy. 2002 Sep;1(3):291-315. doi: 10.2174/1568010023344607. Curr Drug Targets Inflamm Allergy. 2002. PMID: 14561194 Review.
Cited by
-
More to Explore: Further Definition of Risk Factors for COPD - Differential Gender Difference, Modest Elevation in PM2.5, and e-Cigarette Use.Front Physiol. 2021 May 5;12:669152. doi: 10.3389/fphys.2021.669152. eCollection 2021. Front Physiol. 2021. PMID: 34025456 Free PMC article. Review.
-
Regulation of Human MUC7 Mucin Gene Expression by Cigarette Smoke Extract or Cigarette Smoke and Pseudomonas aeruginosa Lipopolysaccharide in Human Airway Epithelial Cells and in MUC7 Transgenic Mice.Open Respir Med J. 2010 Jul 14;4:63-70. doi: 10.2174/1874306401004010063. Open Respir Med J. 2010. PMID: 20802811 Free PMC article.
-
Beverage specific alcohol intake in a population-based study: evidence for a positive association between pulmonary function and wine intake.BMC Pulm Med. 2002 May 8;2:3. doi: 10.1186/1471-2466-2-3. BMC Pulm Med. 2002. PMID: 12000686 Free PMC article.
-
Smoking, Symptoms Improvement, and Total Antioxidant Capacity in Patients with Drug-naive First-episode Schizophrenia: A Prospective Cohort Study.Curr Neuropharmacol. 2024;22(10):1733-1741. doi: 10.2174/1570159X22666231019105328. Curr Neuropharmacol. 2024. PMID: 37859307 Free PMC article.
-
SHP-1 inhibition by 4-hydroxynonenal activates Jun N-terminal kinase and glutamate cysteine ligase.Am J Respir Cell Mol Biol. 2008 Jul;39(1):97-104. doi: 10.1165/rcmb.2007-0371OC. Epub 2008 Feb 14. Am J Respir Cell Mol Biol. 2008. PMID: 18276794 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical